Insilico Medicine Completes Oversubscribed Series E, Bringing Total Funding to $123 Million

Insilico Medicine has finalized its Series E round at $123 million, up from the $110 million first announced in March 2025. The round was led by Value Partners Group, with additional participation from Grand Leader (a wholly-owned subsidiary of Grand Wealth Development Limited) and existing investors including Prosperity7 Ventures. The oversubscribed close reflects continued momentum behind the company’s dual business model—internal drug development and AI platform licensing.

Insilico reports a portfolio of over 30 programs, with 10 having received IND clearance. This includes rentosertib (ISM001-055), now in Phase IIa trials for idiopathic pulmonary fibrosis, and ISM6331, a solid tumor candidate now in early-stage trials in the U.S. and China.

Overall, series E proceeds will support clinical trials, AI model refinement, and expansion of Insilico’s automated lab, with a focus on validating both in-house and partnered drug programs. The company unveiled “Supervisor” in March—a bipedal robot trained to mimic lab techniques for automated reagent handling and equipment operation. This builds on Insilico’s strategy to reduce manual workflows and integrate experimental results directly into its PandaOmics target discovery system.

CEO Alex Zhavoronkov described the raise as both a financial milestone and a signal of investor confidence in Insilico’s AI-plus-wet-lab strategy:

"We are extremely grateful for the continued support from our investors, both new and existing, who share our vision for the future of AI-driven drug discovery and healthcare. The oversubscribed completion of the Series E round is a milestone that not only accelerates the growth of our innovative pipeline and AI technologies but also underscores the industry’s recognition of our capabilities. We are committed to advancing transformative therapies and driving meaningful impact across the pharmaceutical
landscape."

Co-CEO and CSO Feng Ren noted the company is progressing multiple AI-designed compounds in parallel and aiming to be one of the first to achieve clinical validation of an AI-generated drug:

Previously, Insilico Medicine published detailed development benchmarks for 22 AI-designed therapeutics, highlighting accelerated timelines and high preclinical-to-IND success rates.

Topics: Startups & Deals